Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 282.0
(-0.35%)
JPY 282.0
(-0.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 4.15 Billion JPY | -45.97% |
| 2021 | 7.69 Billion JPY | 13.65% |
| 2020 | 6.76 Billion JPY | 0.24% |
| 2019 | 6.75 Billion JPY | 31.6% |
| 2018 | 5.13 Billion JPY | 9.3% |
| 2017 | 4.69 Billion JPY | 16.64% |
| 2016 | 4.02 Billion JPY | -8.33% |
| 2015 | 4.39 Billion JPY | 1.56% |
| 2014 | 4.32 Billion JPY | -5.88% |
| 2013 | 4.59 Billion JPY | 18.19% |
| 2012 | 3.88 Billion JPY | -2.2% |
| 2011 | 3.97 Billion JPY | -3.74% |
| 2010 | 4.12 Billion JPY | 8.46% |
| 2009 | 3.8 Billion JPY | 7.15% |
| 2008 | 3.55 Billion JPY | 8.28% |
| 2007 | 3.28 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 788 Million JPY | 9.75% |
| 2023 Q2 | 718 Million JPY | -1.51% |
| 2023 Q1 | 729 Million JPY | -21.7% |
| 2022 Q3 | 986 Million JPY | -11.09% |
| 2022 FY | 4.15 Billion JPY | -45.97% |
| 2022 Q4 | 931 Million JPY | -5.58% |
| 2022 Q1 | 1.13 Billion JPY | -50.59% |
| 2022 Q2 | 1.1 Billion JPY | -1.95% |
| 2021 Q1 | 2.19 Billion JPY | 0.0% |
| 2021 Q2 | 1.56 Billion JPY | -28.72% |
| 2021 FY | 7.69 Billion JPY | 13.65% |
| 2021 Q4 | 2.28 Billion JPY | 39.4% |
| 2021 Q3 | 1.64 Billion JPY | 4.85% |
| 2020 FY | 6.76 Billion JPY | 0.24% |
| 2020 Q1 | 2.49 Billion JPY | 17.66% |
| 2020 Q3 | 2.16 Billion JPY | 68.5% |
| 2020 Q2 | 1.28 Billion JPY | -48.69% |
| 2019 Q2 | 843.69 Million JPY | -54.28% |
| 2019 FY | 6.75 Billion JPY | 31.6% |
| 2019 Q1 | 1.84 Billion JPY | 42.73% |
| 2019 Q3 | 1.28 Billion JPY | 52.66% |
| 2019 Q4 | 2.12 Billion JPY | 64.88% |
| 2018 Q4 | 1.29 Billion JPY | 9.32% |
| 2018 Q3 | 1.18 Billion JPY | 45.76% |
| 2018 Q1 | 1.6 Billion JPY | 41.74% |
| 2018 Q2 | 811.28 Million JPY | -49.55% |
| 2018 FY | 5.13 Billion JPY | 9.3% |
| 2017 Q3 | 1.17 Billion JPY | 51.7% |
| 2017 Q2 | 775.8 Million JPY | -44.14% |
| 2017 Q1 | 1.38 Billion JPY | 31.6% |
| 2017 FY | 4.69 Billion JPY | 16.64% |
| 2017 Q4 | 1.13 Billion JPY | -3.6% |
| 2016 Q4 | 1.05 Billion JPY | 19.98% |
| 2016 FY | 4.02 Billion JPY | -8.33% |
| 2016 Q3 | 879.63 Million JPY | 25.39% |
| 2016 Q2 | 701.52 Million JPY | -41.63% |
| 2016 Q1 | 1.2 Billion JPY | -5.28% |
| 2015 Q2 | 809.11 Million JPY | -39.08% |
| 2015 Q1 | 1.32 Billion JPY | 8.54% |
| 2015 Q4 | 1.26 Billion JPY | 14.15% |
| 2015 FY | 4.39 Billion JPY | 1.56% |
| 2015 Q3 | 1.11 Billion JPY | 37.37% |
| 2014 Q4 | 1.22 Billion JPY | 15.96% |
| 2014 Q3 | 1.05 Billion JPY | 47.22% |
| 2014 Q1 | 1.72 Billion JPY | 35.9% |
| 2014 Q2 | 716.78 Million JPY | -58.48% |
| 2014 FY | 4.32 Billion JPY | -5.88% |
| 2013 Q1 | 1.38 Billion JPY | 52.5% |
| 2013 FY | 4.59 Billion JPY | 18.19% |
| 2013 Q2 | 707.84 Million JPY | -48.89% |
| 2013 Q4 | 1.27 Billion JPY | 42.87% |
| 2013 Q3 | 889.18 Million JPY | 25.62% |
| 2012 Q4 | 908.14 Million JPY | -1.82% |
| 2012 Q2 | 668.81 Million JPY | -54.54% |
| 2012 FY | 3.88 Billion JPY | -2.2% |
| 2012 Q1 | 1.47 Billion JPY | 54.76% |
| 2012 Q3 | 924.99 Million JPY | 38.3% |
| 2011 Q3 | 817.74 Million JPY | 11.31% |
| 2011 Q2 | 734.65 Million JPY | -33.64% |
| 2011 FY | 3.97 Billion JPY | -3.74% |
| 2011 Q1 | 1.1 Billion JPY | -1.52% |
| 2011 Q4 | 950.67 Million JPY | 16.26% |
| 2010 Q3 | 979.79 Million JPY | 6.77% |
| 2010 Q1 | 930.44 Million JPY | -7.74% |
| 2010 Q4 | 1.12 Billion JPY | 14.74% |
| 2010 FY | 4.12 Billion JPY | 8.46% |
| 2010 Q2 | 917.68 Million JPY | -1.37% |
| 2009 Q4 | 1 Billion JPY | -9.52% |
| 2009 Q3 | 1.11 Billion JPY | 47.99% |
| 2009 Q2 | 753.13 Million JPY | -17.19% |
| 2009 Q1 | 909.49 Million JPY | 6.76% |
| 2009 FY | 3.8 Billion JPY | 7.15% |
| 2008 FY | 3.55 Billion JPY | 8.28% |
| 2008 Q4 | 851.88 Million JPY | 0.0% |
| 2007 FY | 3.28 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 90.474% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.841% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.233% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 97.897% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | -11.258% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 93.666% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 85.678% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.22% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 21.299% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 93.683% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 91.015% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 64.018% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 49.502% |
| Tsumura & Co. | 48.8 Billion JPY | 91.482% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 87.526% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 78.722% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 93.478% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 67.157% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 89.727% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 90.843% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 30.076% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 20.405% |
| MedRx Co., Ltd | 959 Million JPY | -333.472% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -44.655% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -181.64% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -75.352% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 82.797% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 88.268% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -465.439% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 95.835% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -84.159% |